Display options
Cite
Shopnick RI, Brettler DB, Forand P, et al. DDI and liver tests in HIV-1 seropositive haemophiliacs. Haemophilia. 1997;3(1):35-8doi: 10.1046/j.1365-2516.1997.00056.x.
Shopnick, R. I., Brettler, D. B., Forand, P., & McDONALD, M. (1997). DDI and liver tests in HIV-1 seropositive haemophiliacs. Haemophilia : the official journal of the World Federation of Hemophilia, 3(1), 35-8. https://doi.org/10.1046/j.1365-2516.1997.00056.x
Shopnick, R I, et al. "DDI and liver tests in HIV-1 seropositive haemophiliacs." Haemophilia : the official journal of the World Federation of Hemophilia vol. 3,1 (1997): 35-8. doi: https://doi.org/10.1046/j.1365-2516.1997.00056.x
Shopnick RI, Brettler DB, Forand P, McDONALD M. DDI and liver tests in HIV-1 seropositive haemophiliacs. Haemophilia. 1997 Jan;3(1):35-8. doi: 10.1046/j.1365-2516.1997.00056.x. PMID: 27214617.
Copy Download .nbib Format: NLM
Share it on

Haemophilia. 1997 Jan;3(1):35-8. doi: 10.1046/j.1365-2516.1997.00056.x.

DDI and liver tests in HIV-1 seropositive haemophiliacs.

Haemophilia : the official journal of the World Federation of Hemophilia

R I Shopnick, D B Brettler, P Forand, M McDONALD

Affiliations

  1. Division of Hematology, The Medical Center of Central Massachusetts, Worcester, MA, USA,Department of Biostatistics and Epidemiology, The University of Massachusetts School of Public Health and Health Sciences, Amherst, MA, USA.

PMID: 27214617 DOI: 10.1046/j.1365-2516.1997.00056.x

Abstract

Many patients with haemophilia who are HIV-1 seropositive are co-infected with the hepatitis C virus with variable degrees of underlying liver disease. To evaluate whether the use of the antiretroviral agent Dideoxyinosine (DDI) causes worsening of hepatic dysfunction as measured by liver enzyme tests, we reviewed our cohort of patients previously treated with monotherapy with Zidovudine (AZT) and subsequently changed to DDI. Seventeen patients (median age: 34 years, median absolute CD4 lymphocyte cell count: 86 cells μL(-1) ) were included in this study. None had coincident use of other hepatotoxic agents. The median duration of treatment with AZT and DDI was 18 and 15 months, respectively. There was no significant change in liver function tests with the use of DDI and no development of clinical signs of hepatotoxicity. Neither duration of treatment, absolute CD4 lymphocyte cell count, pre-existing elevation of baseline aminotransferase levels nor the use of Pneumocystis carinii prophylaxis therapy resulted in further elevation of liver function tests. Monotherapy with DDI was well tolerated in this cohort of HIV-1-seropositive haemophiliacs with coincident hepatitis C infection.

Blackwell Science Ltd.

Keywords: Dideoxyinosine; HIV; liver function; transaminase levels

Publication Types